Celldex Therapeutics reported $460.2M in Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Amgen AMGN:US $ 64993M 5220M
Applied Genetic Technologies AGTC:US $ 110.41M 16.56M
Aptinyx Inc APTX:US $ 132.65M 1.52M
Arena Pharmaceuticals ARNA:US $ 901.03M 183.63M
Biocept BIOC:US $ 61.95M 11.34M
Bristol Myers Squibb BMY:US $ 110893M 96M
Celldex Therapeutics CLDX:US $ 460.2M 255.65M
Cytrx CYTR:US 17.04M 7.74M
Glaxosmithkline GSK:US $ 78689M 1678M
Immunogen IMGN:US $ 296.8M 4.64M
Merrimack Pharmaceuticals MACK:US $ 16.78M 2.18M
Nektar Therapeutics NKTR:US $ 1277.24M 94.11M
Newlink Genetics NLNK:US $ 106.46M 7.8M
Northwest Biotherapeutics NWBO:US 28.22M 546K
Rigel Pharmaceuticals RIGL:US $ 186.52M 15.08M
Seattle Genetics SGEN:US $ 3977.88M 25.72M